-
Most Recent
Search Results
240 results for BIOF
PHGE Stock Earnings: BiomX Reported Results for Q2 2024
BiomX just reported results for the second quarter of 2024.
PHGE Stock Earnings: BiomX Reported Results for Q4 2023
BiomX just reported results for the fourth quarter of 2023.
PHGE Stock Earnings: BiomX Reported Results for Q1 2024
BiomX just reported results for the first quarter of 2024.
Best-in-Class Metrics for Earnings Growth Keep Bio Rad Laboratories (BIO) a Strong Buy
Bio Rad Laboratories Inc (NYSE:BIO) is ranked as a Strong Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator.…
Analysts Affirm Bio Rad Laboratories (BIO) Buy Rating
Bio Rad Laboratories Inc (NYSE:BIO) is ranked as a Buy using Louis Navellier’s system for investing and his Portfolio Grader stock evaluator. This represents no…
Quant Score Makes Bio Rad Laboratories (BIO) a Buy
Currently, Bio Rad Laboratories Inc (NYSE:BIO) has a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier’s investing methodology. The current Portfolio Grader…
Analysts Affirm Bio Rad Laboratories (BIO) Buy Rating
Bio Rad Laboratories Inc (NYSE:BIO) is ranked as a Buy using Louis Navellier’s system for investing and his Portfolio Grader stock evaluator. This represents no…
Why Is iBio (IBIO) Stock Up 125% Today?
IBIO stock is soaring after the firm announced that it would launch a partnership based on AI and obesity treatments.
MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023
MYNZ stock results show that Mainz Biomed beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
BTMD Stock Earnings: Biote Misses EPS, Beats Revenue for Q1 2024
BTMD stock results show that Biote missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
BTMD Stock Earnings: Biote Misses EPS, Beats Revenue for Q2 2024
BTMD stock results show that Biote missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Bio Rad Laboratories (BIO) a Buy on Solid Quant Score
Bio Rad Laboratories Inc (NYSE:BIO) ranks in the top half of its industry group, Life Sciences Tools & Services, and in the top 25% of…
Rating on Bio Rad Laboratories (BIO) Raised to Strong Buy From a Buy
Currently, Bio Rad Laboratories Inc (NYSE:BIO) has a Strong Buy using the system for investing of Louis Navellier and his Portfolio Grader stock evaluator. BIO…
Bio Rad Laboratories (BIO) a Buy on Strong Quant Score
The current recommendation of Buy for Bio Rad Laboratories Inc (NYSE:BIO) has been derived by using the Portfolio Grader stock evaluator of Louis Navellier, which…
Quant Score Metrics Drive Bio Rad Laboratories (BIO) to Strong Buy
Bio Rad Laboratories Inc (NYSE:BIO) is one of 33 companies within the Life Sciences Tools & Services GICS industry group, which is in turn part…
Outstanding Measures for Earnings Momentum Keep Bio Rad Laboratories (BIO) a Strong Buy
Currently, Bio Rad Laboratories Inc (NYSE:BIO) has a Strong Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. BIO…
Bio Rad Laboratories (BIO) a Strong Buy on High-Level Quant Score
With a $7.6 billion market value, Bio Rad Laboratories Inc (NYSE:BIO) ranks in the upper half of its industry group, Life Sciences Tools & Services,…
Up 600% Year-to-Date, Sell iBio Stock While It’s Still Flying High
The latest iBio news isn’t good. It’s taken too long for IBIO to develop a coronavirus vaccine and now the opportunity has disappeared.
iBio Is in a Healthy Position With Covid-19 Vaccine Push
iBio stock is still a buy but it needs to land contracts with some major vaccine developers as we get closer to a Covid-19 vaccine
5 Best Stocks Under $5 This Week
Markets were lackluster this week, but ATA, Jaguar Animal Health, Biocept, Aware and CVSL were all tigers.
BioNano: The Stock Has Gotten Ahead of Itself
BioNano has a promising clinical platform. It needs to generate more revenues before BNGO stock will be worth its current price, however.
A Lack of Progress Keeps IBIO Shares As a Sell
Investors bought the Covid-19 hype in IBIO stock. With little progress made, however, reality is setting in, which means the fade should continue.
Even a Profitable BofA Shows Banking’s Risks
Financials are propping up earnings season — thanks to easy comparisons. But they have miles to go and many headwinds to overcome before returning to…
Why Is BiomX (PHGE) Stock Up 147% Today?
BiomX stock is rocketing higher on Wednesday with heavy trading of PHGE shares after announcing a new merger agreement.
6 – 10 of 240 results
